Pharsight

1. List of Orladeyo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10329260	BIOCRYST	Human plasma kallikrein inhibitors	Mar, 2035 (11 years from now)
US10125102	BIOCRYST	Human plasma kallikrein inhibitors	Apr, 2035 (12 years from now)
US10662160	BIOCRYST	Crystalline salts of a plasma kallikrein inhibitor	Nov, 2039 (16 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11230530	BIOCRYST	Human plasma kallikrein inhibitors	Mar, 2035 (11 years from now)
US10689346	BIOCRYST	Human plasma kallikrein inhibitors	Mar, 2035 (11 years from now)
US11117867	BIOCRYST	Crystalline salts of a plasma kallikrein inhibitor	Nov, 2039 (16 years from now)

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Dec 3, 2027
New Chemical Entity Exclusivity (NCE)	Dec 3, 2025

NCE-1 date: 2024-12-03

Market Authorisation Date: 03 December, 2020

Treatment: Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older

Dosage: CAPSULE;ORAL